News

Latest news

15/04/2026

brainstrust plays role in major new glioblastoma trials development in Yorkshire

Charity News | Research News
Read more
01/04/2026

Vorasidenib approved for NHS use in England: no-one left behind

Campaign News | Research News
Read more
24/03/2026

Vorasidenib approved in Scotland – people living with grade 2 brain tumours in England must not be left behind.

Brain News | Campaign News | Charity News
Read more
26/02/2026

Brain tumour data: Statistics that shock, but can also bring hope

Brain Tumour Data | Charity News | Press Releases
Read more
05/02/2026

England National Cancer Plan.

Campaign News | Charity News
Read more
19/12/2025

An investment in hope: National Brain Tumour Consortium receives NIHR funding

Brain News | Campaign News | Charity News
Read more
15/12/2025

Navigating Christmas After Loss

Campaign News | Charity News
Read more
03/12/2025

Alfred Duke supports brainstrust and his brother Harrison with 72 Hole Golf Day Challenge

Do your own thing | Fundraising News
Read more
03/12/2025

Towards Excellence – A review of brain tumour care for children across the UK

Campaign News | Charity News | Research News
Read more
21/11/2025

Wear Grey 2025: Thank You!

Campaign News | Fundraising
Read more
13/11/2025

Jack Faint becomes the first person ever to run the length of India

Campaign News | Charity News | Fundraising
Read more
12/11/2025

Encouraging new data on Vorasidenib brings hope for people with IDH-mutant glioma

Campaign News | Charity News | Research News
Read more
23/10/2025

How Nasprias is Helping brainstrust this Wear Grey

Do your own thing | Fundraising News
Read more
20/10/2025

NICE’s latest draft guidance on Vorasidenib is not a final decision.

Campaign News | Charity News | Research News
Read more
16/10/2025

Gene therapy breakthrough for glioblastoma (GBM)

Brain News | Campaign News | Charity News | Research News
Read more
18/09/2025

Jack Faint runs the length of India to support brainstrust.

Campaign News | Charity News | Fundraising
Read more

Subscribe to our mailing list to hear about all the latest news, events, research and resources

Fields marked with an * are required